顽固性心力衰竭患者应用左卡尼汀联合左西孟旦的临床效果及不良反应率分析

Clinical efficacy and adverse reaction rate of L-carnitine combined with levosimendan in patients with refractory heart failure

目的探讨顽固性心力衰竭患者在临床治疗中应用左卡尼汀联合左西孟旦的临床效果,并对其不良反应概率进行分析。方法选取本院2016年9月至2018年3月收治患有顽固性心力衰竭患者共80例作为实验研究对象,采用随机数字分配法将患者分为实验组和对照组,每组40例,对照组采用常规治疗及左卡尼汀单药疗法,实验组患者在此基础上增加左西孟旦进行治疗,完成治疗后观察两组患者临床疗效,并比较两组患者治疗中发生不良反应事件的概率。结果比较两组患者治疗有效率,差异具有统计学意义(P<0.05);治疗后两组患者各项指标均出现改善,实验组患者LVEDD、LVESD均高于对照组且LVEF、CI均低于对照组,差异具有统计学意义(P<0.05);两组患者不良反应事件发生概率比较差异无统计学意义。结论顽固性心力衰竭患者的临床治疗过程中应用左卡尼汀联合左西孟旦效果良好,具有推广价值。

Objective To explore the clinical effect of levonetine combined with levonucitine in clinical treatment of patients with refractory heart failure, and to analyze its adverse reaction probability. Methods From September 2016 to March 2018 were treated with a total of 80 patients with refractory heart failure as experimental research object, USES the random number distribution method divided the patients into the experimental group and the control group, 40 cases in each group, control group using conventional treatment and 1-carnitine single-agent therapy, on the basis of the experimental group patients increased leosimendan treatment, after treatment to observe the clinical curative effect, two groups of patients and compare the two groups of the probability of adverse events in patients. Results The therapeutic efficiency of the two groups was compared, and the difference was statistically significant （P〈0.05）. After treatment, all the indicators of patients in the two groups were improved, LVEDD and LVESD in the experimental group were higher than those in the control group, and LVEF and CI were lower than those in the control group, and the differ- ence was statistically significant （P〈0.05）. There was no statistically significant difference in the incidence of adverse events between the two groups. Conclusion The application of 1-carnitine combined with 1-simontin in the clinical treatment of patients with refractory heart failure has good effect and is worthy of promotion.